NACF 2017. P247. Efficacy and Safety of Tezacaftor/Ivacaftor in Patients Aged ≥12 Years with CF…
jwood@krftwrk.caNovember 27, 2017
ATS 2017. A4678 - Benralizumab Significantly Reduced Oral Corticosteroid Dosages and Asthma Exacerbation Rates for…
jwood@krftwrk.caJune 23, 2017
ATS 2017. A4729 - Ivacaftor/Lumacaftor Improves Six Minute Walk Test Distance and Improves Lung Clearance…
jwood@krftwrk.caJune 23, 2017
ERS 2016. PA1257. Ivacaftor-as effective in clinical practice? A. Aziz et al. Results: 15 patients with…
jwood@krftwrk.caOctober 5, 2016
ERS 2016. LBA OA1969: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase…
jwood@krftwrk.caOctober 5, 2016
Cystic Fibrosis ATS 2016. A5585 - Characterization of Ivacaftor and Lumacaftor Using BioMAP® Profiling -…
jwood@krftwrk.caJuly 7, 2016
Pulmonary Arterial Hypertension ATS 2016. A6315 - The RESPITE Study: Riociguat in Patients with PAH…
jwood@krftwrk.caJune 27, 2016
Chronic Obstructive Pulmonary Disease ATS 2016. A6817 - Improvement in Lung Function and Symptom Control…
jwood@krftwrk.caJune 27, 2016
Non-Cystic Fibrosis Bronchiectasis ATS 2016. A1775 - ORBIT-3 and ORBIT-4: Design of a Phase 3…
jwood@krftwrk.caJune 27, 2016
